JATT II Acquisition (JATT)
Market Price (5/30/2026): $10.5 | Market Cap: $-Sector: Financials | Industry: Multi-Sector Holdings
JATT II Acquisition (JATT)
Market Price (5/30/2026): $10.5Market Cap: $-Sector: FinancialsIndustry: Multi-Sector Holdings
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Trading close to highsDist 52W High is -4.3% | Stock price has recently run up significantly6M Rtn6 month market price return is 159%, 12M Rtn12 month market price return is 159% High stock price volatilityVol 12M is 159% Key risksJATT key risks include [1] a heavy dependence on successful Phase 2 clinical trial outcomes for its candidates ZB-168 and Torudokimab, Show more. |
| Trading close to highsDist 52W High is -4.3% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 159%, 12M Rtn12 month market price return is 159% |
| High stock price volatilityVol 12M is 159% |
| Key risksJATT key risks include [1] a heavy dependence on successful Phase 2 clinical trial outcomes for its candidates ZB-168 and Torudokimab, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
1/31/2026 to 5/29/2026| Return | Correlation | |
|---|---|---|
| JATT | 158.9% | |
| Market (SPY) | 9.6% | 0.1% |
| Sector (XLF) | -3.0% | 20.9% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| JATT | 158.9% | |
| Market (SPY) | 11.5% | 0.1% |
| Sector (XLF) | -0.7% | 20.9% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| JATT | 158.9% | |
| Market (SPY) | 38.0% | 0.1% |
| Sector (XLF) | 7.4% | 20.9% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2023 to 5/29/2026| Return | Correlation | |
|---|---|---|
| JATT | 57.8% | |
| Market (SPY) | 89.0% | 19.3% |
| Sector (XLF) | 63.2% | 13.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| JATT Return | 2% | 3% | -53% | -15% | 0% | 157% | 7% |
| Peers Return | 79% | -36% | -49% | 1% | -24% | 232% | 50% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| JATT Win Rate | 25% | 75% | 42% | 25% | 0% | 20% | |
| Peers Win Rate | 50% | 25% | 33% | 42% | 17% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| JATT Max Drawdown | -2% | -1% | -88% | -55% | 0% | -5% | |
| Peers Max Drawdown | -31% | -41% | -60% | -44% | -45% | -1% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BEBE, ACAA, AEAQ, ALOV, ALUB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/29/2026 (YTD)
How Low Can It Go
| Event | JATT | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -36.0% | -9.5% |
| % Gain to Breakeven | 56.2% | 10.5% |
| Time to Breakeven | 882 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -51.9% | -6.7% |
| % Gain to Breakeven | 108.0% | 7.1% |
| Time to Breakeven | 46 days | 31 days |
In The Past
JATT II Acquisition's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | JATT | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -36.0% | -9.5% |
| % Gain to Breakeven | 56.2% | 10.5% |
| Time to Breakeven | 882 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -51.9% | -6.7% |
| % Gain to Breakeven | 108.0% | 7.1% |
| Time to Breakeven | 46 days | 31 days |
In The Past
JATT II Acquisition's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About JATT II Acquisition (JATT)
AI Analysis | Feedback
Here are 1-3 brief analogies for JATT II Acquisition (Zura Bio Limited):
- An early-stage Regeneron, but entirely focused on novel immunology drugs.
- Like a mini-AbbVie, with a focused pipeline of innovative immunology therapies.
- A startup Genentech, specializing in advancing breakthrough immunology treatments.
AI Analysis | Feedback
- ZB-168: An anti-IL7Rα inhibitor targeting diseases driven by IL7 and TSLP biological pathways.
- Torudokimab: A fully human, high-affinity monoclonal antibody designed to neutralize IL33.
AI Analysis | Feedback
Based on the provided description, Zura Bio Limited (the operating company under JATT II Acquisition, symbol: JATT) is a clinical-stage biotechnology company. Its primary focus is on advancing immunology assets like ZB-168 and Torudokimab through clinical development stages (Phase 1b and Phase 2).
At this stage of development, Zura Bio Limited is not yet commercializing or selling its therapeutic products to individuals or other companies. Therefore, the company does not currently have major customers for its products or services in the traditional sense.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Zura Bio Limited, which resulted from the business combination with JATT Acquisition Corp, faces several key risks inherent to its nature as a clinical-stage biotechnology company.-
Clinical Trial and Regulatory Approval Risk: Zura Bio Limited's success is heavily dependent on the successful development and regulatory approval of its product candidates, including ZB-168 and Torudokimab, which are currently in Phase 2 development programs. Clinical trials are inherently lengthy, expensive, and subject to a high rate of failure, even in later stages such as Phase 2. Industry data indicates a low probability (approximately 20%) for a compound to advance from Phase 1 trials to market approval, with many failures stemming from a lack of efficacy, safety, or unfavorable toxicity profiles. Moreover, securing regulatory approval is a challenging and often unpredictable process.
-
Capital Requirements and Potential for Future Dilution: As a clinical-stage company with a limited operating history, Zura Bio Limited requires substantial capital to fund its ongoing research and development activities, including its current and planned Phase 2 clinical trials. Although the company has reported a cash runway anticipated to extend through 2027 or 2028, depending on the source, the biotechnology sector often experiences tightening risk tolerance from investors, making future fundraising challenging. Any need for additional capital could lead to further equity offerings and potential dilution for existing shareholders.
-
Competition and Market Differentiation: The biotechnology industry is characterized by rapid advancements and intense competition. Zura Bio Limited operates in a competitive landscape, and even if its product candidates successfully complete clinical trials and gain regulatory approval, there is no guarantee of widespread market acceptance. A key risk for its assets, such as tibulizumab (ZB-106) in the hidradenitis suppurativa (HS) market, is the need to demonstrate clinically meaningful differentiation against existing or emerging therapies, especially when the value of certain targets (like BAFF) remains unproven in crowded markets.
AI Analysis | Feedback
null
AI Analysis | Feedback
Zura Bio Limited (Nasdaq: JATT) is a clinical-stage biotechnology company developing immunology assets. The addressable markets for its main product candidates, ZB-168 and Torudokimab, are as follows:
ZB-168 (anti IL7R α inhibitor)
ZB-168 is being developed for autoimmune diseases where IL-7 or TSLP signaling is implicated, including Type 1 Diabetes, Multiple Sclerosis, and Alopecia Areata.
- Type 1 Diabetes: The global market for Type 1 Diabetes is estimated to be valued at USD 18.09 billion in 2026 and is projected to reach USD 28.30 billion by 2033. Another estimate places the global market at USD 37.60 billion in 2025, with a projection to reach USD 79.14 billion by 2035. North America is a significant region in this market, expected to hold 39.4% of the global market share in 2026.
- Alopecia Areata: A Phase 2 clinical trial for ZB-168 in alopecia areata is planned for 2024. The global alopecia areata market was valued at USD 10.37 billion in 2024 and is projected to reach USD 19.39 billion by 2032. In 2025, the market size across the seven major markets (the United States, EU4, the United Kingdom, and Japan) was approximately USD 850 million, with the U.S. alone accounting for around USD 500 million.
- Multiple Sclerosis: ZB-168 has completed Phase 1/1b clinical studies for Multiple Sclerosis. The global multiple sclerosis therapeutic market was valued at USD 29.51 billion in 2025 and is anticipated to reach approximately USD 52.32 billion by 2035. Another valuation places the global market at USD 27.39 billion in 2024, projected to grow to USD 38.62 billion by 2030. North America held the largest market share in 2024, representing 38.28% of the global market.
Torudokimab (IL-33 neutralizer)
Torudokimab is being evaluated for allergy or respiratory-related indications, including severe asthma and chronic obstructive pulmonary disease (COPD).
- Severe Asthma Treatment Market: The global severe asthma treatment market is valued at USD 24.30 billion in 2025 and is expected to reach USD 39.96 billion by 2035. The broader global asthma therapeutics market was valued at USD 29.29 billion in 2025 and is anticipated to reach around USD 48.94 billion by 2035. North America held a significant share of the global asthma therapeutics market, accounting for 51.00% in 2025.
- Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: The global chronic obstructive pulmonary disease (COPD) treatment market size is expected to be valued at USD 21.04 billion in 2025 and is anticipated to reach around USD 34.59 billion by 2035. North America generated more than 42% of the revenue share in this market in 2025.
- Combined COPD and Asthma Therapeutics Market: The global market for COPD and asthma therapeutics was valued at USD 92.30 billion in 2024 and is estimated to reach USD 155.25 billion by 2030. In 2024, North America held the largest revenue share, at 40.1%.
AI Analysis | Feedback
Zura Bio Limited (NASDAQ: ZURA), formerly JATT II Acquisition, is a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases. As a clinical-stage entity, the company currently generates no product revenue. Expected drivers of future revenue growth over the next 2-3 years are primarily tied to the successful advancement of its pipeline candidates and the potential for strategic partnerships. Here are 3-5 expected drivers of future revenue growth for Zura Bio Limited:- Positive Clinical Trial Outcomes for Tibulizumab (ZB-106) in Phase 2 Studies: Zura Bio's lead product candidate, tibulizumab (ZB-106), is currently undergoing two global Phase 2 clinical trials. The TibuSHIELD study is evaluating the drug for hidradenitis suppurativa (HS), with topline data anticipated in the fourth quarter of 2026. The TibuSURE study is investigating tibulizumab for systemic sclerosis (SSc), with topline data expected in the first half of 2027. Successful results from these trials would be a significant de-risking event, potentially paving the way for further clinical development and eventual commercialization, or attracting lucrative licensing partnerships.
- Advancement of Crebankitug (ZB-168) and Torudokimab (ZB-880) into Later-Stage Clinical Development: Beyond tibulizumab, Zura Bio is evaluating future development strategies for crebankitug (ZB-168) and torudokimab (ZB-880), both of which have completed Phase 1/1b studies. Zura Bio plans to prepare crebankitug for Phase 2 readiness, and for torudokimab, the company is monitoring external clinical data which may inform its future development plans, with an additional data readout anticipated in 2026. Progressing these assets through clinical development would strengthen the company's pipeline and broaden its future market opportunities.
- Expansion into New Therapeutic Indications: Zura Bio aims to develop a portfolio of therapeutic indications for its immunology assets, particularly ZB-168, building on existing Phase 1b data. Successfully identifying and pursuing new therapeutic areas for its drug candidates would expand their potential market reach and contribute to long-term revenue streams.
- Strategic Partnerships and Licensing Agreements: As a clinical-stage biotechnology company, Zura Bio can generate revenue through strategic partnerships and licensing agreements. Such agreements often involve upfront payments, milestone payments upon achieving specific development or regulatory goals, and future royalties on product sales. Analyst forecasts indicate potential revenue in the 2025-2027 timeframe, which for a company at this stage, could include proceeds from such partnerships.
AI Analysis | Feedback
nullTrade Ideas
Select ideas related to JATT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | EEFT | Euronet Worldwide | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04242026 | HOMB | Home BancShares | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 1.5% | 1.5% | 0.0% |
| 03312026 | HBAN | Huntington Bancshares | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 7.1% | 7.1% | 0.0% |
| 03312026 | NP | Neptune Insurance | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 3.9% | 3.9% | 0.0% |
| 03272026 | JKHY | Jack Henry & Associates | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.3% | 0.3% | -4.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.02 |
| Mkt Cap | 0.3 |
| Rev LTM | - |
| Op Inc LTM | - |
| FCF LTM | - |
| FCF 3Y Avg | - |
| CFO LTM | - |
| CFO 3Y Avg | - |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | - |
| Rev Chg 3Y Avg | - |
| Rev Chg Q | - |
| QoQ Delta Rev Chg LTM | - |
| Op Inc Chg LTM | - |
| Op Inc Chg 3Y Avg | - |
| Op Mgn LTM | - |
| Op Mgn 3Y Avg | - |
| QoQ Delta Op Mgn LTM | - |
| CFO/Rev LTM | - |
| CFO/Rev 3Y Avg | - |
| FCF/Rev LTM | - |
| FCF/Rev 3Y Avg | - |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | - |
| P/Op Inc | - |
| P/EBIT | - |
| P/E | - |
| P/CFO | - |
| Total Yield | - |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | - |
| D/E | 0.0 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.4% |
| 3M Rtn | 1.0% |
| 6M Rtn | 1.0% |
| 12M Rtn | 1.0% |
| 3Y Rtn | 1.0% |
| 1M Excs Rtn | -5.8% |
| 3M Excs Rtn | -9.2% |
| 6M Excs Rtn | -11.0% |
| 12M Excs Rtn | -27.7% |
| 3Y Excs Rtn | -81.8% |
Earnings Returns History
Updated 5/29/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.